Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 2466

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1
Chunk 2466
---
 Two Years One Year Abstain Broker Non-Vote

27,236,885
3,242,231 1,788,193 765,048 26,758,574

As
previously disclosed, at the Meeting, the following directors either determined to not stand for election or resigned: Michelle Berrey
(who also resigned as CEO), Jack Elias, Bill Owens, Suren Ajjarapu and Amy Griffith.

11

Our
Strategy and Competitive Strengths

Our
goal is to facilitate the flow of academic discoveries from bench-to-bedside by efficiently carrying out the translational and clinical
development required to advance them commercially. The number of potential opportunities at research universities and medical centers
is large but only a small fraction of these opportunities is currently tapped by venture capitalists or pharmaceutical companies. There
is a growing yet still small number of accelerator programs and incubators aiming to bridge the bench-to-bedside gap at specific institutions;
however, the gap remains wide and we believe this presents an attractive opportunity for us to become an industry leader by addressing
a need to accelerate the advancement of therapeutics that can address significant unmet medical needs.

The
core elements that we believe differentiate our business model include:

    ●
    Harnessing
    inventions and technologies from research universities and medical centers. We search for opportunities wherever they can be found,
    and we believe “hidden gems” can be uncovered by our team. We are experienced at identifying and sourcing breakthrough
    discoveries at academic and research institutions, including our current partnerships with Brown University and Rhode Island Hospital.
    We know how to assess and test their scientific merits and commercial relevance, and we have extensive experience working with these
    institutions and licensing their assets. For example, our leadership team has evaluated thousands of innovations, taken multiple
    products through IND filings and into clinical development, and been involved in the launch of 8 biotech companies.

    ●
    Developing
    new drug therapies through an operationally efficient, evidence-based and milestone-driven approach. Once we select an asset for
    development, we pursue what we believe are appropriate development strategies that we aim to execute efficiently by leveraging contract
    research and contract manufacturing organizations, or CROs and CMOs, respectively, and other drug development experts and consultants.
    We aim to rapidly and efficiently advance our product candidates to objective critical decision points. We direct resources toward
    the opportunities that we believe are the most promising, and we discontinue programs that do not meet our performance thresholds